Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

337M-8

Sigma-Aldrich

TAG-72 (B72.3) Mouse Monoclonal Antibody

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

UNSPSC-Code:
12352203
NACRES:
NA.41
Preise und Verfügbarkeit sind derzeit nicht verfügbar.

Biologische Quelle

mouse

Qualitätsniveau

100
500

Konjugat

unconjugated

Antikörperform

culture supernatant

Antikörper-Produkttyp

primary antibodies

Klon

B72.3, monoclonal

Beschreibung

For In Vitro Diagnostic Use in Select Regions (See Chart)

Form

buffered aqueous solution

Speziesreaktivität

human

Verpackung

vial of 0.1 mL concentrate (337M-84)
vial of 0.5 mL concentrate (337M-85)
bottle of 1.0 mL predilute (337M-87)
vial of 1.0 mL concentrate (337M-86)
bottle of 7.0 mL predilute (337M-88)

Hersteller/Markenname

Cell Marque®

Methode(n)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:100-1:500

Isotyp

IgG1κ

Kontrolle

lung adenocarcinoma

Versandbedingung

wet ice

Lagertemp.

2-8°C

Visualisierung

cytoplasmic

Allgemeine Beschreibung

Anti-B72.3 recognizes a high molecular weight glycoprotein called TAG-72 that is present in human adenocarcinomas and in lesser amounts, non-neoplastic tissues. It has also been found to be useful to distinguish between mesothelioma and adenocarcinoma, however, false positive reactions can occur so results must be interpreted with the utmost caution.

Qualität


IVD
IVD
IVD
RUO

Verlinkung

TAG-72 Positive Control Slides, Product No. 337S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).

Physikalische Form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide

Angaben zur Herstellung

Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.

Sonstige Hinweise

For Technical Service please contact: 800-665-7284 or email: [email protected]

Rechtliche Hinweise

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Sie haben nicht das passende Produkt gefunden?  

Probieren Sie unser Produkt-Auswahlhilfe. aus.

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number
0000230924
0000230924
0000413472
0000413468
0000413468

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Suche nach COA

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

W W Johnston et al.
Human pathology, 17(5), 501-513 (1986-05-01)
Monoclonal antibody B72.3 has been shown to be reactive with a high-molecular-weight glycoprotein complex termed TAG(tumor-associated glycoprotein)-72. By the avidin-biotin immunoperoxidase method, fine needle aspirates and corresponding surgically excised tumor tissues from both malignant and benign tissues were analyzed for
K G Osteen et al.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 11(3), 216-220 (1992-07-01)
Compared with the degree of investigation of stage-specific expression of tumor-associated glycoprotein-72 (TAG-72) in fundal endometrium, other regions of the female reproductive tract have not received comparable attention. Regional, cell-type-specific, and temporal differences in estrogen receptor and progesterone receptor distribution
A Thor et al.
Cancer research, 46(6), 3118-3124 (1986-06-01)
Murine monoclonal antibody B72.3, prepared against a membrane-enriched extract of human metastatic carcinoma, was reacted with a spectrum of adult and fetal human tissues using avidin-biotin-complex immunohistochemical techniques to evaluate the expression of the reactive tumor associated glycoprotein (TAG)-72 antigen.
The use of Mab B72.3 in the diagnosis of human carcinoma
Schlom J, et al.
J. Tumor Marker oncol., 2, 95-112 (1987)
David C Chhieng et al.
Human pathology, 34(10), 1016-1021 (2003-11-11)
Ovarian carcinoma has a high mortality rate, because most ovarian carcinomas are detected at a late stage. Traditional therapies, such as surgical debulking and chemotherapy, have not been successful in improving the long-term survival of these patients. Alternative therapies targeting
Alle zugehörigen Dokumente anzeigen

Fragen

Bewertungen

Kein Beurteilungswert

Aktive Filter

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.